The company offers treatment of severe allergic rhinitis with allergen immunotherapy, including sublingual products, subcutaneous products, enzyme-linked immunosorbent assay components and prescription services. In June 2026, Stallergenes Greer announced a strategic investment of over €125 million by 2030 in its Antony site in France to expand and upgrade its industrial capacity.
Cyborg Score Rationale
Stallergenes Greer demonstrates strong strategic positioning through consistent acquisitions (Entomon in January 2026, Palforzia in 2023), significant capital investment, and market leadership in allergen immunotherapy. The company operates across 46 countries with 1,200+ employees and growing R&D activity, though private status limits financial transparency.
Top Insights
Announced €125M+ strategic investment in French manufacturing facility through 2030 (June 2026)
Acquired Entomon s.r.l., Italy's only company extracting pure Hymenoptera venom for immunotherapy, with close expected by January 2026
Presenting clinical evidence on allergen immunotherapy long-term outcomes at EAACI 2026 congress (June 12-15, Istanbul)
Planning 12% workforce increase in France during 2026 to support operational growth
Named Competitors
Xolair — Anti-IgE monoclonal antibody for allergic conditions
Palforzia — Oral immunotherapy for peanut allergy
Grastek/Oralair — Sublingual immunotherapy tablets for grass/birch pollen allergy
Ragwitek — Sublingual immunotherapy tablet for ragweed allergy
Recent Developments
(June 2026) Announced €125M+ investment in Antony manufacturing facility through 2030
(June 2026) Presenting new clinical evidence on allergen immunotherapy at EAACI 2026 congress
(January 2026) Acquired Entomon s.r.l. for venom immunotherapy manufacturing capabilities
(May 2023) Acquired Palforzia oral immunotherapy for peanut allergy from Nestlé
Open the full interactive Stallergenes Greer report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.